Galectin Therapeutics' Belapectin Shows 49% Reduction in Liver Varices, Stock Hits 52-Week High
核心洞察
Galectin Therapeutics' belapectin demonstrated a 49.3% reduction in new varices development at the 2 mg/kg dose in its NAVIGATE Phase 2/3 trial for MASH cirrhosis (搜索).
The company reported improved Q2 2025 financials with a reduced net loss of $7.6 million and secured $13.8 million in cash plus a $10 million credit line extending operations through mid-2026.
GALT stock reached a 52-week high of $5.10, gaining over 119% since December 2024, driven by promising clinical data and strong financial positioning.
Galectin Therapeutics Inc. (NASDAQ: GALT) has achieved significant clinical and financial milestones with its lead candidate belapectin, a galectin-3 (搜索) inhibitor targeting chronic liver diseases. The company's stock surged to a 52-week high of $5.10 on September 9, 2025, reflecting investor confidence in the drug's therapeutic potential and the company's strengthened financial position.
Clinical Progress in MASH Cirrhosis Treatment
The ongoing NAVIGATE Phase 2/3 trial has delivered compelling efficacy data for belapectin in treating MASH cirrhosis (搜索) and portal hypertension (搜索). At the 18-month readout, the trial demonstrated a 49.3% reduction in new varices development at the 2 mg/kg dose compared to placebo. The intent-to-treat population showed a ≥40% reduction in new varices versus placebo, with an even more significant reduction observed in the per-protocol group.
Beyond varices prevention, belapectin showed significant improvements in liver stiffness compared to placebo, addressing a critical aspect of liver fibrosis (搜索) management. The drug maintained a favorable safety profile throughout the trial, with no serious drug-related adverse events reported.
"We are also analyzing additional biomarkers and expect to present those results later this year," stated Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, indicating further insights into belapectin's mechanism of action are forthcoming.
Regulatory and Development Advantages
Belapectin holds Fast Track Designation from the FDA, positioning Galectin Therapeutics as the only company exclusively focused on MASH cirrhosis (搜索) and portal hypertension (搜索) treatment. The drug's carbohydrate-based molecular structure allows for natural degradation by the body, contributing to its low toxicity profile. Patent protection extends through 2032, providing substantial intellectual property coverage.
The company has expanded its development pipeline beyond liver disease, advancing an oncology program with combination therapy approaches. Galectin has filed an Investigational New Drug (IND) application for head and neck cancer (搜索) treatment, which has received FDA clearance to proceed.
Financial Strengthening and Operational Runway
Galectin Therapeutics reported improved financial performance in Q2 2025, with a reduced net loss of $7.6 million ($0.12 per share) compared to the prior year's loss of $12.4 million ($0.20 per share). The improvement was attributed to lower research and development expenses.
As of June 30, 2025, the company maintained $13.8 million in cash and cash equivalents. Additionally, Galectin secured a $10 million credit line earlier in 2025, extending its operational runway through mid-2026 and providing financial stability to advance clinical programs.
Market Performance and Investor Interest
The positive clinical and financial developments have translated into strong stock performance. GALT shares gained over 7% in the past week and more than 50% in recent months, with the stock climbing 119.83% from $2.32 in December 2024 to its 52-week high of $5.10 in September 2025.
At the H.C. Wainwright 27th Annual Global Investment Conference in early September, CEO Joel Lewis and Chief Medical Officer Dr. Khurram Jamil engaged with investors, highlighting confidence in belapectin's development trajectory and outlining upcoming clinical milestones.
The combination of promising clinical data, regulatory momentum, and strengthened financial position positions Galectin Therapeutics as a notable player in the biotech sector, particularly given the significant unmet medical need in liver fibrosis (搜索) management and the company's focused approach to addressing these challenging conditions.